| 產(chǎn)品編號(hào) | bs-1545R-Cy3 |
| 英文名稱1 | Rabbit Anti-TPA/Cy3 Conjugated antibody |
| 中文名稱 | Cy3標(biāo)記的組織型纖溶酶原激活劑抗體 |
| 別 名 | TPA Tissue Plasminogen Activator; Plasminogen activator tissue; Plasminogen activator tissue type; Plasminogen Activator Tissue Type Isoform 1 Preproprotein; PLAT; Reteplase; t PA; t-PA; T Plasminogen Activator; Tissue plasminogen activator (t PA); PATISS; Tissue type plasminogen activator; TPA1; AU020998; AW212668; D8Ertd2e; MGC18508; TPA_HUMAN; Tissue-type plasminogen activator; t-plasminogen activator; Alteplase; Tissue-type plasminogen activator chain B. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 研究領(lǐng)域 | 心血管 免疫學(xué) 神經(jīng)生物學(xué) 激酶和磷酸酶 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | Mouse, (predicted: Human, Rat, Pig, Cow, Horse, Rabbit, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 28/58kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Tissue-type plasminogen activator chain B |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: This gene encodes tissue-type plasminogen activator, a secreted serine protease which converts the proenzyme plasminogen to plasmin, a fibrinolytic enzyme. Tissue-type plasminogen activator is synthesized as a single chain which is cleaved by plasmin to a two chain disulfide linked protein. This enzyme plays a role in cell migration and tissue remodeling. Increased enzymatic activity causes hyperfibrinolysis, which manifests as excessive bleeding; decreased activity leads to hypofibrinolysis which can result in thrombosis or embolism. Alternative splicing of this gene results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]. Function: Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Plays a direct role in facilitating neuronal migration. Subunit: Heterodimer of chain A and chain B held by a disulfide bond. Forms a heterodimer with SERPINA5. Binds to fibrin with high affinity. This interaction leads to an increase in the catalytic efficiency of the enzyme between 100-fold and 1000-fold, due to an increase in affinity for plasminogen. Similarly, binding to heparin increases the activation of plasminogen. Binds to annexin A2, cytokeratin-8, fibronectin and laminin. Binds to mannose receptor and the low-density lipoprotein receptor-related protein (LRP1); these proteins are involved in TPA clearance. Yet unidentified interactions on endothelial cells and vascular smooth muscle cells (VSMC) lead to a 100-fold stimulation of plasminogen activation. In addition, binding to VSMC reduces TPA inhibition by PAI-1 by 30-fold. Binds LRP1B; binding is followed by internalization and degradation. Subcellular Location: Secreted. Tissue Specificity: Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk. Post-translational modifications: The single chain, almost fully active enzyme, can be further processed into a two-chain fully active form by a cleavage after Arg-310 catalyzed by plasmin, tissue kallikrein or factor Xa. Differential cell-specific N-linked glycosylation gives rise to two glycoforms, type I (glycosylated at Asn-219) and type II (not glycosylated at Asn-219). The single chain type I glycoform is less readily converted into the two-chain form by plasmin, and the two-chain type I glycoform has a lower activity than the two-chain type II glycoform in the presence of fibrin. N-glycosylation of Asn-152; the bound oligomannosidic glycan is involved in the interaction with the mannose receptor. Characterization of O-linked glycan was studied in Bowes melanoma cell line. DISEASE: Note=Increased activity of TPA results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of TPA results in hypofibrinolysis that can lead to thrombosis or embolism. Similarity: Belongs to the peptidase S1 family. Contains 1 EGF-like domain. Contains 1 fibronectin type-I domain. Contains 2 kringle domains. Contains 1 peptidase S1 domain. Database links: Entrez Gene: 5327 Human Omim: 173370 Human SwissProt: P00750 Human Unigene: 491582 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 組織型纖溶酶原激活劑tPA是絲氨酸蛋白酶家族的一員,其主要的生物學(xué)功能是激活纖溶酶原轉(zhuǎn)變?yōu)槔w溶酶. 近年來(lái)經(jīng)研究表明t-PA參與循環(huán)系統(tǒng)的溶血栓過(guò)程之外,t-PA還在神經(jīng)系統(tǒng)中也發(fā)揮了重要的作用，t-PA參與了癲癇和早老型癡呆癥等神經(jīng)系統(tǒng)疾病的發(fā)生和發(fā)展，在學(xué)習(xí)和記憶等生理過(guò)程中也發(fā)揮了重要作用。 |
